Title: 2015 ACVIM Forum Research Abstract Program Document date: 2015_5_27
ID: 3pnuj5ru_698
Snippet: In conclusion, capromorelin was well-tolerated in cats dosed orally at 6 mg/kg for 91 consecutive days. Further, this study indicates an expected adequate safety margin for capromorelin as the dose used was 39 the proposed clinical dose. Capromorelin is a ghrelin agonist that, when dosed orally in laboratory dogs, has been shown to stimulate food intake, weight gain, growth hormone (GH) and insulin-like growth factor-1 (IGF-1) (Zollers et al. 201.....
Document: In conclusion, capromorelin was well-tolerated in cats dosed orally at 6 mg/kg for 91 consecutive days. Further, this study indicates an expected adequate safety margin for capromorelin as the dose used was 39 the proposed clinical dose. Capromorelin is a ghrelin agonist that, when dosed orally in laboratory dogs, has been shown to stimulate food intake, weight gain, growth hormone (GH) and insulin-like growth factor-1 (IGF-1) (Zollers et al. 2014 ). This randomized, placebo-controlled study was performed to determine if capromorelin would also increase food consumption, promote weight gain and increase serum IGF-1 levels in laboratory cats.
Search related documents:
Co phrase search for related documents- capromorelin safety margin and food consumption: 1
- capromorelin safety margin and safety margin: 1
- clinical dose and food consumption: 1
- clinical dose and food intake: 1
- clinical dose and orally dose: 1, 2, 3, 4, 5
- clinical dose and safety margin: 1, 2
- clinical dose and serum level: 1, 2, 3, 4
- clinical dose and weight gain: 1, 2, 3
- food consumption and GH growth hormone: 1
- food consumption and ghrelin agonist: 1, 2
- food consumption and growth hormone: 1
Co phrase search for related documents, hyperlinks ordered by date